| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioHarvest Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.16 |
| 52 Week High | CA$0.20 |
| 52 Week Low | CA$0.10 |
| Beta | 1.52 |
| 1 Month Change | -7.10% |
| 3 Month Change | 4.67% |
| 1 Year Change | 12.95% |
| 3 Year Change | -28.64% |
| 5 Year Change | n/a |
| Change since IPO | 64.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8MV | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -0.2% | -0.4% |
| 1Y | 12.9% | 6.8% | 8.6% |
Return vs Industry: 8MV exceeded the German Personal Products industry which returned 6.8% over the past year.
Return vs Market: 8MV exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| 8MV volatility | |
|---|---|
| 8MV Average Weekly Movement | 11.2% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8MV's share price has been volatile over the past 3 months.
Volatility Over Time: 8MV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Ilan Sobel | www.bioharvest.com |
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells.
BioHarvest Sciences Inc. Fundamentals Summary
| 8MV fundamental statistics | |
|---|---|
| Market cap | €97.09m |
| Earnings (TTM) | -€11.57m |
| Revenue (TTM) | €11.67m |
8.3x
P/S Ratio-8.4x
P/E RatioIs 8MV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8MV income statement (TTM) | |
|---|---|
| Revenue | US$12.67m |
| Cost of Revenue | US$7.04m |
| Gross Profit | US$5.63m |
| Other Expenses | US$18.20m |
| Earnings | -US$12.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 44.45% |
| Net Profit Margin | -99.15% |
| Debt/Equity Ratio | -138.2% |
How did 8MV perform over the long term?
See historical performance and comparison